CC
TBPH icon

Corton Capital’s Theravance Biopharma TBPH Stock Holding History

Corton Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,243
Closed -$199K – 398
2025
Q1 		$199K Sell
22,243
-11,103
-33% -$103K 0.66% 67
2024
Q4 		$314K Buy
+33,346
New +$303K 0.18% 88
2024
Q2 		– Sell
-14,888
Closed -$134K – 732
2024
Q1 		$134K Buy
14,888
+2,676
+22% +$24.8K 0.05% 458
2023
Q4 		$137K Buy
+12,212
New +$123K 0.04% 524

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Corton Capital's TBPH Position: Q2 2025 in Review

Corton Capital sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 22,243 shares — an estimated $199K sold.

Corton Capital first reported a position in TBPH in Q4 2023 and held it in 4 quarters. The position peaked at $314K in Q4 2024. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • Corton Capital reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 22,243 Theravance Biopharma shares in Q2 2025, an estimated $199K.
  • Corton Capital first reported a position in Theravance Biopharma in Q4 2023 and held it in 4 quarters.
  • Corton Capital's Theravance Biopharma position peaked at $314K in Q4 2024.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.